News
UCBJY
162.02
+0.97%
1.55
Weekly Report: what happened at UCBJY last week (0406-0410)?
Weekly Report · 21h ago
Barclays Remains a Buy on UCB SA (0NZT)
TipRanks · 1d ago
Barclays Sticks to Their Buy Rating for UCB SA (0NZT)
TipRanks · 6d ago
Weekly Report: what happened at UCBJY last week (0330-0403)?
Weekly Report · 04/06 10:44
Weekly Report: what happened at UCBJY last week (0323-0327)?
Weekly Report · 03/30 10:44
Barclays Sticks to Its Buy Rating for UCB SA (0NZT)
TipRanks · 03/30 06:35
UCB SA Reports Long-Term Bimzelx Data In Hidradenitis Suppurativa
NASDAQ · 03/27 16:38
Barclays Sticks to Its Buy Rating for UCB SA (0NZT)
TipRanks · 03/23 10:45
Weekly Report: what happened at UCBJY last week (0316-0320)?
Weekly Report · 03/23 10:40
TD Cowen Sticks to Its Buy Rating for UCB SA (0NZT)
TipRanks · 03/20 18:25
Berenberg Bank Reaffirms Their Buy Rating on UCB SA (0NZT)
TipRanks · 03/17 06:26
Weekly Report: what happened at UCBJY last week (0309-0313)?
Weekly Report · 03/16 10:39
UCB SA (0NZT) Gets a Buy from Barclays
TipRanks · 03/16 07:36
PGIM Jennison Health Sciences Fund Q4 2025 Key Contributors And Detractors
Seeking Alpha · 03/16 03:25
TD Cowen Keeps Their Buy Rating on UCB SA (0NZT)
TipRanks · 03/13 08:25
UCB SA (0NZT) Receives a Hold from Kepler Capital
TipRanks · 03/13 01:39
Barclays Sticks to Their Buy Rating for UCB SA (0NZT)
TipRanks · 03/12 06:37
AbbVie’s Skyrizi beaten by UCB’s Bimzelx in psoriatic arthritis
Seeking Alpha · 03/11 12:31
Weekly Report: what happened at UCBJY last week (0302-0306)?
Weekly Report · 03/09 10:39
Barclays Sticks to Their Buy Rating for UCB SA (0NZT)
TipRanks · 03/09 08:06
More
Webull provides a variety of real-time UCBJY stock news. You can receive the latest news about Ucb S A through multiple platforms. This information may help you make smarter investment decisions.
About UCBJY
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.